Let’s tackle malaria with Natixis!
Involved since 2005 in the fight against malaria, Natixis is launching an awareness campaign: "Ensemble, plaquons le palu" [Let’s tackle malaria together!] jointly with Plan France, Institut Pasteur, and with the support of Racing Metro92.
Watch the misadventures of Mousty on the rugby field on our YouTube channel
Let’s tackle malaria with Natixis! (Interview de Marion Locatelli et d'Agnès Guiral)
Malaria: a serious but curable disease
Every year, malaria affects over 200 million people and claims more than 600,000 lives (source: WHO). The disease is due to a parasite and is transmitted by a bite from an infected female mosquito. It exists in sub-Saharan Africa and in some countries of Southeast Asia and hinders the economic development in these areas. There still is no vaccine today. Insecticide-treated mosquito nets are the most efficient way to prevent malaria. Though efficient malaria treatments exist, resistance to antimalarial drugs is growing. Since 2005, Natixis has been involved with NGOs and research facilities to help fight malaria.
Natixis’ involvement consists in:
- Helping to protect populations by informing them and contributing to the distribution of mosquito nets
- Supporting medical research to improve care for malaria patients.
- Create public awareness of this disease.
Our partners in the fight against malaria
The NGO Plan France works to help children grow up healthy. Since 2005, with the support of Natixis, it has carried out programs for the prevention of and the fight against malaria in Cameroon, Burkina Faso and Togo. In these three countries, 75,100 mosquito nets were distributed and the lives of 45,900 children under the age of five and as many pregnant women were protected.
At Institut Pasteur, ten research teams in Paris and many more on site via the Institut Pasteur international network work on malaria research.
Natixis finances a number of the Institute’s research programs focused on understanding the antimalarial drug resistance phenomenon in order to devise new treatments.